NO995006L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number: NO995006L
Authority: NO; Norway
Prior art keywords: new connections; compounds; processes; formula; preparation
Prior art date: 1997-04-15

Application number

NO995006A

Other languages

English (en)

Norwegian (no)

Other versions

NO995006D0 (no

Inventor

David Cheshire

Martin Cooper

David Donald

Philip Thorne

Original Assignee

Astra Pharma Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-15

Filing date

1999-10-14

Publication date

1999-10-14

1999-10-14 Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod

1999-10-14 Publication of NO995006D0 publication Critical patent/NO995006D0/no

1999-10-14 Publication of NO995006L publication Critical patent/NO995006L/no

Links

150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
DSBOPXOKGKIRSG-UHFFFAOYSA-N pyrrolo[3,4-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)C2=CN=CC2=N1 DSBOPXOKGKIRSG-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)

NO995006A 1997-04-15 1999-10-14 Nye forbindelser NO995006L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9701398A SE9701398D0 (sv)	1997-04-15	1997-04-15	Novel compounds
PCT/SE1998/000640 WO1998046606A1 (en)	1997-04-15	1998-04-07	Novel compounds

Publications (2)

Publication Number	Publication Date
NO995006D0 NO995006D0 (no)	1999-10-14
NO995006L true NO995006L (no)	1999-10-14

Family

ID=20406576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO995006A NO995006L (no)	1997-04-15	1999-10-14	Nye forbindelser

Country Status (21)

Country	Link
US (1)	US6028074A (de)
EP (1)	EP0975636B1 (de)
JP (1)	JP2001520645A (de)
KR (1)	KR20010006350A (de)
CN (1)	CN1259951A (de)
AT (1)	ATE245648T1 (de)
AU (1)	AU733066B2 (de)
BR (1)	BR9808540A (de)
CA (1)	CA2286078A1 (de)
DE (1)	DE69816608T2 (de)
EE (1)	EE9900465A (de)
HU (1)	HUP0002104A3 (de)
ID (1)	ID22746A (de)
IL (1)	IL132153A0 (de)
IS (1)	IS5198A (de)
NO (1)	NO995006L (de)
PL (1)	PL336230A1 (de)
SE (1)	SE9701398D0 (de)
SK (1)	SK135699A3 (de)
TR (1)	TR199902538T2 (de)
WO (1)	WO1998046606A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9801399D0 (sv)	1998-04-21	1998-04-21	Astra Pharma Prod	Method and apparatus for filling containers
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US6875786B2 (en)	2001-03-01	2005-04-05	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1575916B1 (de)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesteraseaktivität und regulation der durch phosphodiesterase-1-b vermittelten signalvermittlung im hirn
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
EP1901701A4 (de) *	2005-05-24	2012-05-02	David M Ott	Körperpflege- und medizinische produkte mit gebundenen schwefelorganischen gruppen
WO2006133261A2 (en)	2005-06-06	2006-12-14	Intra-Cellular Therapies, Inc.	Organic compounds
AU2007256633B2 (en) *	2006-06-06	2013-09-12	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008063505A1 (en)	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
ES2588238T3 (es) *	2007-12-06	2016-10-31	Intra-Cellular Therapies, Inc.	Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
EP2939676A1 (de)	2007-12-06	2015-11-04	Intra-Cellular Therapies, Inc.	Organische Verbindungen
AU2009322903A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
AU2009322899A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
PE20110922A1 (es)	2008-12-06	2012-01-22	Intra Cellular Therapies Inc	DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
EA201170769A1 (ru)	2008-12-06	2012-02-28	Интра-Селлулар Терапиз, Инк.	Органические соединения
MX2011005934A (es) *	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
PE20120834A1 (es)	2009-03-23	2012-07-25	Glenmark Pharmaceuticals Sa	Derivados de furopirimidindiona como moduladores de trpa1
ES2456515T3 (es) *	2009-03-23	2014-04-22	Glenmark Pharmaceuticals S.A.	Derivados de pirimidindiona fusionados como moduladores de TRPA1
US8623880B2 (en)	2009-03-23	2014-01-07	Glenmark Pharmaceuticals S.A.	Fused pyrimidine-dione derivatives as TRPA1 modulators
BRPI1009372A2 (pt)	2009-03-23	2016-05-31	Glenmark Pharmaceuticals Sa	compostos, composição farmacêutica e respectivos usos
EP2434895A4 (de)	2009-05-13	2013-08-07	Intra Cellular Therapies Inc	Organische verbindungen
EP2434894B1 (de)	2009-05-29	2016-08-31	Novartis AG	Verfahren zur verabreichung von thrombopoietinagonisten
WO2011016861A2 (en)	2009-08-05	2011-02-10	Intra-Cellular Therapies, Inc.	Novel regulatory proteins and inhibitors
US9763948B2 (en)	2010-05-31	2017-09-19	Intra-Cellular Therapies, Inc.	PDE1 inhibitory compounds and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
EP2575817A4 (de)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Organische verbindungen
EP2717877B1 (de)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organische verbindungen
AU2013273118B2 (en)	2012-06-08	2015-11-05	Glenmark Pharmaceuticals S.A.	Amides of 2-amino-4-arylthiazole compounds and their salts
EP2956141A4 (de)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	Neuartige verwendungen
ES2717688T3 (es)	2013-03-15	2019-06-24	Intra Cellular Therapies Inc	Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
DK3157926T3 (da)	2014-06-20	2019-08-19	Intra Cellular Therapies Inc	Organiske forbindelser
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
CA2961212C (en)	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
BR112017012007B1 (pt)	2014-12-06	2022-11-01	Intra-Cellular Therapies, Inc	Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
WO2016090382A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Organic compounds
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
CN109311886B (zh) *	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]三唑并[4,5-d]嘧啶衍生物
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0063381A1 (de) *	1981-04-22	1982-10-27	Byk Gulden Lomberg Chemische Fabrik GmbH	Neue Pyrazolo(3,4-d)pyrimidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US4603203A (en) *	1983-12-14	1986-07-29	Takeda Chemical Industries, Ltd.	3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (de) *	1986-03-14	1988-07-27	Takeda Chemical Industries, Ltd.	Pyrazolo[3,4-d]pyrimidinderivate, ihre Herstellung und Verwendung
DK0674624T3 (da) *	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines

1997
- 1997-04-15 SE SE9701398A patent/SE9701398D0/xx unknown
1998
- 1998-04-07 DE DE69816608T patent/DE69816608T2/de not_active Expired - Fee Related
- 1998-04-07 AU AU70909/98A patent/AU733066B2/en not_active Ceased
- 1998-04-07 KR KR1019997009435A patent/KR20010006350A/ko not_active Withdrawn
- 1998-04-07 CN CN98806075A patent/CN1259951A/zh active Pending
- 1998-04-07 CA CA002286078A patent/CA2286078A1/en not_active Abandoned
- 1998-04-07 WO PCT/SE1998/000640 patent/WO1998046606A1/en not_active Ceased
- 1998-04-07 EP EP98917859A patent/EP0975636B1/de not_active Expired - Lifetime
- 1998-04-07 IL IL13215398A patent/IL132153A0/xx unknown
- 1998-04-07 BR BR9808540-9A patent/BR9808540A/pt not_active IP Right Cessation
- 1998-04-07 EE EEP199900465A patent/EE9900465A/xx unknown
- 1998-04-07 PL PL98336230A patent/PL336230A1/xx unknown
- 1998-04-07 SK SK1356-99A patent/SK135699A3/sk unknown
- 1998-04-07 JP JP54380398A patent/JP2001520645A/ja not_active Ceased
- 1998-04-07 ID IDW991207A patent/ID22746A/id unknown
- 1998-04-07 TR TR1999/02538T patent/TR199902538T2/xx unknown
- 1998-04-07 HU HU0002104A patent/HUP0002104A3/hu unknown
- 1998-04-07 AT AT98917859T patent/ATE245648T1/de not_active IP Right Cessation
- 1998-08-07 US US09/068,304 patent/US6028074A/en not_active Expired - Fee Related
1999
- 1999-09-27 IS IS5198A patent/IS5198A/is unknown
- 1999-10-14 NO NO995006A patent/NO995006L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO995006D0 (no)	1999-10-14
ID22746A (id)	1999-12-09
US6028074A (en)	2000-02-22
EE9900465A (et)	2000-04-17
IL132153A0 (en)	2001-03-19
ATE245648T1 (de)	2003-08-15
DE69816608T2 (de)	2004-04-15
IS5198A (is)	1999-09-27
DE69816608D1 (de)	2003-08-28
SE9701398D0 (sv)	1997-04-15
PL336230A1 (en)	2000-06-19
AU7090998A (en)	1998-11-11
BR9808540A (pt)	2000-05-23
SK135699A3 (en)	2000-05-16
JP2001520645A (ja)	2001-10-30
HUP0002104A2 (hu)	2001-01-29
AU733066B2 (en)	2001-05-03
EP0975636A1 (de)	2000-02-02
HUP0002104A3 (en)	2002-03-28
WO1998046606A1 (en)	1998-10-22
TR199902538T2 (xx)	2000-02-21
CN1259951A (zh)	2000-07-12
KR20010006350A (ko)	2001-01-26
CA2286078A1 (en)	1998-10-22
EP0975636B1 (de)	2003-07-23

Legal Events

Date	Code	Title	Description
2002-11-18	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20000311L (no)	2000-03-21	Nye forbindelser
NO20000313L (no)	2000-03-22	Nye forbindelser
NO995006D0 (no)	1999-10-14	Nye forbindelser
NO993027L (no)	1999-08-20	Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
CA2272705A1 (en)	1998-06-04	Fused bicyclic pyrimidine derivatives
SE9702001D0 (sv)	1997-05-28	Novel compounds
NO20030381L (no)	2003-02-24	Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
AU3799789A (en)	1990-01-18	Novel benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
CA2263561A1 (en)	1998-02-19	Thienopyrimidines
TR199800012T1 (xx)	1998-04-21	Piroloprimidinler ve preparasyon i�in tatbikler.
NO20002788D0 (no)	2000-05-31	Nye forbindelser
AP9901435A0 (en)	1999-03-31	Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2216535A1 (en)	1996-10-03	Protein kinase c inhibitors
NO904694D0 (no)	1990-10-30	Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
CA2181175A1 (en)	1995-07-20	Dihydro Pyrazolopyrroles
NO901684D0 (no)	1990-04-17	Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO903088L (no)	1991-01-14	Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
MX9702382A (es)	1998-02-28	Nuevos derivados de pirimidona con actividad antifungica.
NO172537C (no)	1993-08-04	Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater
NO167028C (no)	1991-09-25	Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolo(3,4-d)pyrimidinderivater
NO984651L (no)	1998-12-03	Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO913644D0 (no)	1991-09-16	Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
PT1025101E (pt)	2003-04-30	Derivados de nafto-imidazo¬1,2-a\|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
NO900972L (no)	1990-09-04	Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO165544C (no)	1991-02-27	Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon.